002038 双鹭药业
已收盘 05-15 15:00:00
资讯
新帖
简况
股市必读:双鹭药业(002038)5月13日收盘跌5.91%,主力净流出427.72万元
证券之星 · 05-14
股市必读:双鹭药业(002038)5月13日收盘跌5.91%,主力净流出427.72万元
双鹭药业及相关人员被采取行政监管措施;英硅智能又达成一项合作
21世纪经济报道 · 05-09
双鹭药业及相关人员被采取行政监管措施;英硅智能又达成一项合作
双鹭药业(002038):公司及相关当事人收到深圳证券交易所纪律处分决定
同壁财经 · 05-06
双鹭药业(002038):公司及相关当事人收到深圳证券交易所纪律处分决定
双鹭药业(002038.SZ)获得ω-3脂肪酸乙酯90软胶囊药品注册证书
智通财经 · 05-06
双鹭药业(002038.SZ)获得ω-3脂肪酸乙酯90软胶囊药品注册证书
双鹭药业(002038)2026年一季报简析:净利润同比下降287.33%,存货明显上升
证券之星 · 04-30
双鹭药业(002038)2026年一季报简析:净利润同比下降287.33%,存货明显上升
图解双鹭药业年报:第四季度单季净利润同比下降751.73%
证券之星 · 04-29
图解双鹭药业年报:第四季度单季净利润同比下降751.73%
4月15日双鹭药业(002038)涨停分析:生物药获批、GLP-1申报驱动
证券之星 · 04-15
4月15日双鹭药业(002038)涨停分析:生物药获批、GLP-1申报驱动
国办一纸文件定调药价,创新药爆发!涨停名单还在拉长
格隆汇 · 04-15
国办一纸文件定调药价,创新药爆发!涨停名单还在拉长
4月9日双鹭药业(002038)龙虎榜数据:机构净买入2252.22万元(3日),北向资金净买入940.16万元(3日)
证券之星 · 04-09
4月9日双鹭药业(002038)龙虎榜数据:机构净买入2252.22万元(3日),北向资金净买入940.16万元(3日)
双鹭药业:4月7日接受机构调研,西部证券、景顺长城等多家机构参与
证券之星 · 04-07
双鹭药业:4月7日接受机构调研,西部证券、景顺长城等多家机构参与
3月30日双鹭药业(002038)涨停分析:GLP-1进展、独家急救药、创投浮盈驱动
证券之星 · 03-30
3月30日双鹭药业(002038)涨停分析:GLP-1进展、独家急救药、创投浮盈驱动
异动快报:双鹭药业(002038)3月30日9点31分触及涨停板
证券之星 · 03-30
异动快报:双鹭药业(002038)3月30日9点31分触及涨停板
异动快报:双鹭药业(002038)3月27日10点8分触及涨停板
证券之星 · 03-27
异动快报:双鹭药业(002038)3月27日10点8分触及涨停板
双鹭药业:奥司他韦可用于流感治疗
证券之星 · 02-03
双鹭药业:奥司他韦可用于流感治疗
双鹭药业:该公司不是公司子公司
证券之星 · 02-03
双鹭药业:该公司不是公司子公司
双鹭药业:度拉糖肽注射液已经申报上市即将受理
证券之星 · 02-03
双鹭药业:度拉糖肽注射液已经申报上市即将受理
异动快报:双鹭药业(002038)2月2日9点33分触及跌停板
证券之星 · 02-02
异动快报:双鹭药业(002038)2月2日9点33分触及跌停板
双鹭药业:奥司他韦订单数量有所增加
证券之星 · 2025-12-02
双鹭药业:奥司他韦订单数量有所增加
双鹭药业:截至2025年9月30日股东总户数为54,779
证券之星 · 2025-12-02
双鹭药业:截至2025年9月30日股东总户数为54,779
双鹭药业收盘上涨1.02%,滚动市盈率86.04倍,总市值70.89亿元
金融界 · 2025-03-10
双鹭药业收盘上涨1.02%,滚动市盈率86.04倍,总市值70.89亿元
加载更多
公司概况
公司名称:
北京双鹭药业股份有限公司
所属行业:
医药制造业
上市日期:
2004-09-09
主营业务:
北京双鹭药业股份有限公司的主营业务是基因工程及相关药物的研究开发和生产经营。公司的主要产品是生物、生化药、化学药。公司系国家火炬计划重点高新技术企业、国家技术创新示范企业、中关村生物产业创新基地、北京市中关村核心区生物工程和新医药产业联盟理事长单位、北京市工业企业知识产权运用示范企业、北京市国际科技合作基地、北京市高新技术成果转化示范企业,海淀园博士后科研工作站,北京市“G20”一期工程优秀企业、二期入选企业,中关村“十百千工程”重点培育企业,全资子公司双鹭生物被评为北京市“专精特新”中小企业。2025年公司核心竞争力未发生重大变化。
发行价格:
12.00
{"stockData":{"symbol":"002038","market":"SZ","secType":"STK","nameCN":"双鹭药业","latestPrice":6.11,"timestamp":1778828598000,"preClose":6.26,"halted":0,"volume":38371944,"delay":0,"changeRate":-0.024,"floatShares":852000000,"shares":1027000000,"eps":-0.4666,"marketStatus":"已收盘","change":-0.15,"latestTime":"05-15 15:00:00","open":6.24,"high":6.28,"low":6.07,"amount":237000000,"amplitude":0.0335,"askPrice":6.12,"askSize":423,"bidPrice":6.11,"bidSize":464,"shortable":0,"etf":0,"ttmEps":-0.4666,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":6.26,"symbolType":"stock","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":6.89,"lowLimit":5.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1027350000,"isCdr":false,"pbRate":1.26,"roa":"--","roe":"--","epsLYR":-0.34,"committee":-0.214987,"marketValue":6277000000,"turnoverRate":0.045,"status":1,"floatMarketCap":5205000000},"requestUrl":"/m/hq/s/002038","defaultTab":"news","newsList":[{"id":"2635073056","title":"股市必读:双鹭药业(002038)5月13日收盘跌5.91%,主力净流出427.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635073056","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635073056?lang=zh_cn&edition=full","pubTime":"2026-05-14 03:21","pubTimestamp":1778700083,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘,双鹭药业报收于6.53元,下跌5.91%,换手率9.46%,成交量80.63万手,成交额5.29亿元。来自交易信息汇总:前10个交易日主力资金累计净流出8239.95万元,股价累计下跌11.81%。交易信息汇总股价提醒5月13日双鹭药业收盘报6.53元,跌5.91%,当日成交8062.86万元。资金流向5月13日主力资金净流出427.72万元,占总成交额0.81%;游资资金净流出232.45万元,占总成交额0.44%;散户资金净流入660.17万元,占总成交额1.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400003744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002038","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634495981","title":"双鹭药业及相关人员被采取行政监管措施;英硅智能又达成一项合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2634495981","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634495981?lang=zh_cn&edition=full","pubTime":"2026-05-09 08:30","pubTimestamp":1778286639,"startTime":"0","endTime":"0","summary":"政策动向国家卫健委就“基层卫生健康综合试验区改革创新经验”有关情况举行新闻发布会国家卫生健康委于5月8日在山东省潍坊市寿光市晨鸣国际大酒店君德厅召开新闻发布会,介绍基层卫生健康综合试验区改革创新经验有关情况,并答记者问。国家卫健委相关负责人表示,基层医疗卫生机构是医疗卫生服务体系的重要组成部分,是守护群众健康的第一道防线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605093732130971.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605093732130971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0188","BK0239","002038"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633310801","title":"双鹭药业(002038):公司及相关当事人收到深圳证券交易所纪律处分决定","url":"https://stock-news.laohu8.com/highlight/detail?id=2633310801","media":"同壁财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633310801?lang=zh_cn&edition=full","pubTime":"2026-05-06 21:44","pubTimestamp":1778075040,"startTime":"0","endTime":"0","summary":"双鹭药业(002038)5月6日发布公告,北京双鹭药业股份有限公司近日收到深圳证券交易所下发的《关于北京双鹭药业股份有限公司及相关当事人给予纪律处分的决定》(深证上〔2026〕591号)和监管函。 资料显示,双鹭药业(002038)主营业务为基因工程及相关药物的研究开发和生产经营。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-06/doc-inhwyqfz3259573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["399001","BK0028","002038","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633218597","title":"双鹭药业(002038.SZ)获得ω-3脂肪酸乙酯90软胶囊药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2633218597","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633218597?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:56","pubTimestamp":1778061411,"startTime":"0","endTime":"0","summary":"智通财经APP讯,双鹭药业(002038.SZ)发布公告,公司于近日收到国家药品监督管理局(以下简称“国家药监局”)核准签发的ω-3脂肪酸乙酯90软胶囊(商品名:欣复尔®)《药品注册证书》。ω-3脂肪酸乙酯90软胶囊,主要组成成分为ω-3脂肪酸乙酯,本品为软胶囊剂,主要用于降低重度高甘油三酯血症(≥500mg/L)成年患者的甘油三酯(TG)水平。该产品最早由挪威Pronova公司开发,1994年在意大利获批上市,2004年在美国获批上市,商品名为Lovaza。该产品目前国内已有7家企业上市。目前该品种未进入国家医保。该产品由公司昌平基地新增生产车间生产,需通过GMP认证后方能上市销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","002038","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631520183","title":"双鹭药业(002038)2026年一季报简析:净利润同比下降287.33%,存货明显上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2631520183","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631520183?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:27","pubTimestamp":1777501641,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期双鹭药业发布2026年一季报。截至本报告期末,公司营业总收入1.37亿元,同比下降18.98%,归母净利润-8611.44万元,同比下降287.33%。本报告期双鹭药业存货明显上升,存货同比增幅达37.67%。本次财报公布的各项数据指标表现一般。公司历史上的财报相对一般,公司上市来已有年报22份,亏损年份2次,显示生意模式比较脆弱。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000020515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631580302","title":"图解双鹭药业年报:第四季度单季净利润同比下降751.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631580302","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631580302?lang=zh_cn&edition=full","pubTime":"2026-04-29 02:45","pubTimestamp":1777401915,"startTime":"0","endTime":"0","summary":"证券之星消息,双鹭药业2025年年报显示,当年度公司主营收入6.24亿元,同比下降5.57%;归母净利润-3.47亿元,同比下降368.77%;扣非净利润-4613.0万元,同比下降156.03%;其中2025年第四季度,公司单季度主营收入1.65亿元,同比上升37.57%;单季度归母净利润-4.88亿元,同比下降751.73%;单季度扣非净利润-7546.49万元,同比下降1836.29%;负债率14.55%,投资收益1338.04万元,财务费用-483.2万元,毛利率62.14%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900007245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627401346","title":"4月15日双鹭药业(002038)涨停分析:生物药获批、GLP-1申报驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2627401346","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627401346?lang=zh_cn&edition=full","pubTime":"2026-04-15 15:34","pubTimestamp":1776238472,"startTime":"0","endTime":"0","summary":"证券之星消息,双鹭药业4月15日涨停收盘,收盘价8.07元。今日双鹭药业涨停的可能因素有:聚乙二醇化人粒细胞刺激因子注射液等重磅生物药即将获批;GLP-1周制剂及日制剂完成临床研究、GLP-1-Fc融合蛋白度拉糖肽已提交注册申请;独家硝酸甘油喷雾剂具急救优势且纳入国家医保;公司产品结构由单一转向多品种支撑,抗风险能力增强;董事长自愿补足5000万元投资损失差额,显著提振市场信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500022658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","159839","002038","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405121","title":"国办一纸文件定调药价,创新药爆发!涨停名单还在拉长","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405121","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405121?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:33","pubTimestamp":1776234822,"startTime":"0","endTime":"0","summary":"政策组合拳出击","market":"us","thumbnail":"https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-f3f18d25-b1d2-4d82-b91d-544aa33cb569.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4422353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0122","BK0132","02162","BK0185","600572","BK1583","002038","BK0197","600488","06978","LU0196878994.USD","BK0070","BK0077","BK0097","BK0102","BK0209","301408","BK0060","BK1587","159992","BK0028","600267","BK0239","06990","BK1574","BK1161","000919","000788","BK0250","BK0188","BK0012","BK0096","002589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626900625","title":"4月9日双鹭药业(002038)龙虎榜数据:机构净买入2252.22万元(3日),北向资金净买入940.16万元(3日)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626900625","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626900625?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:12","pubTimestamp":1775725974,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月9日公布的交易公开信息显示,双鹭药业因连续三个交易日内,跌幅偏离值累计达到20%的证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年4月9日收盘,双鹭药业报收于7.38元,下跌6.35%,换手率18.82%,成交量160.35万手,成交额12.35亿元。从龙虎榜公布的三日买卖数据来看,机构合计净买入2252.22万元,北向资金合计净买入940.16万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900027215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002038","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625195491","title":"双鹭药业:4月7日接受机构调研,西部证券、景顺长城等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2625195491","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625195491?lang=zh_cn&edition=full","pubTime":"2026-04-07 23:32","pubTimestamp":1775575940,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年4月7日双鹭药业发布公告称公司于2026年4月7日接受机构调研,西部证券、景顺长城、招商资管参与。药效学方面,DT678片 6mg对血小板聚集的抑制作用高于 3mg剂量组和阳性对照组,DT678片 3mg组和氯吡格雷片阳性对照组对血小板聚集的抑制作用接近。DT678片单次、多次给药后安全性良好。目前,国内心血管病患者约 3.3亿,其中冠心病患者约 1100万,心绞痛患者需常备急救药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700033881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","002038","BK0183","BK0188","BK0028","002673","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623556392","title":"3月30日双鹭药业(002038)涨停分析:GLP-1进展、独家急救药、创投浮盈驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2623556392","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623556392?lang=zh_cn&edition=full","pubTime":"2026-03-30 15:40","pubTimestamp":1774856417,"startTime":"0","endTime":"0","summary":"证券之星消息,双鹭药业3月30日涨停收盘,收盘价7.27元。该股于9点30分涨停,9次打开涨停,截止收盘封单资金为1553.09万元,占其流通市值0.25%。3月30日的资金流向数据方面,主力资金净流出2011.98万元,占总成交额1.72%,游资资金净流入148.16万元,占总成交额0.13%,散户资金净流入1863.82万元,占总成交额1.6%。近5日资金流向一览见下表:该股为肝素,减肥药,基因编辑概念热股,当日肝素概念上涨2.26%,减肥药概念上涨1.68%,基因编辑概念上涨1.65%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000015644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","002038"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623364209","title":"异动快报:双鹭药业(002038)3月30日9点31分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2623364209","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623364209?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:35","pubTimestamp":1774834535,"startTime":"0","endTime":"0","summary":"证券之星3月30日盘中消息,9点31分双鹭药业(002038)触及涨停板。其所属行业化学制药目前上涨。领涨股为舒泰神。该股为肝素,长寿药NMN,疫苗概念热股,当日肝素概念上涨0.68%。3月27日的资金流向数据方面,主力资金净流入1.13亿元,占总成交额30.28%,游资资金净流出4913.29万元,占总成交额13.21%,散户资金净流出6345.45万元,占总成交额17.06%。近5日资金流向一览见下表:双鹭药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000003644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002038","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622816518","title":"异动快报:双鹭药业(002038)3月27日10点8分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2622816518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622816518?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:10","pubTimestamp":1774577435,"startTime":"0","endTime":"0","summary":"证券之星3月27日盘中消息,10点8分双鹭药业触及涨停板。其所属行业化学制药目前上涨。领涨股为美诺华。该股为减肥药,基因编辑,阿尔茨海默病概念热股,当日减肥药概念上涨2.47%,基因编辑概念上涨2.23%,阿尔茨海默病概念上涨2.02%。3月26日的资金流向数据方面,主力资金净流出2198.29万元,占总成交额6.88%,游资资金净流入2270.33万元,占总成交额7.1%,散户资金净流出72.04万元,占总成交额0.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700016229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002038","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608477428","title":"双鹭药业:奥司他韦可用于流感治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2608477428","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608477428?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:12","pubTimestamp":1770102735,"startTime":"0","endTime":"0","summary":"证券之星消息,双鹭药业(002038)02月02日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,问下公司在抗流感方面有哪些药物,预防流感有哪些药物,glp-1年复一年,现在还需要多少年???双鹭药业回复:您好,公司产品奥司他韦可用于流感治疗,此外公司产品胸腺五肽、白介素-2为免疫增强剂,可提升免疫力预防流感;长效GLP-1类产品度拉糖肽目前已提交上市申请,待受理。产品注册检验合格。如有最新进展公司会适时交流。谢谢关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300020159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002038","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608106847","title":"双鹭药业:该公司不是公司子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2608106847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608106847?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:06","pubTimestamp":1770102390,"startTime":"0","endTime":"0","summary":"证券之星消息,双鹭药业(002038)02月02日在投资者关系平台上答复投资者关心的问题。投资者提问:福建双鹭医药有限公司是否为子公司?双鹭药业回复:您好,该公司不是公司子公司。谢谢关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300020114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002038","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608184742","title":"双鹭药业:度拉糖肽注射液已经申报上市即将受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2608184742","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608184742?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:06","pubTimestamp":1770102387,"startTime":"0","endTime":"0","summary":"证券之星消息,双鹭药业(002038)02月02日在投资者关系平台上答复投资者关心的问题。投资者提问:司美格鲁肽口服药即将获批,贵司的度拉糖肽和利拉鲁肽迟迟未能申报,是否考虑放弃申报,从而节约研发费用花在落后产品上。双鹭药业回复:您好,度拉糖肽注射液已经申报上市即将受理,注册检验已通过。如有最新情况公司会适时沟通。谢谢关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300020109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002038","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608807833","title":"异动快报:双鹭药业(002038)2月2日9点33分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2608807833","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608807833?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:36","pubTimestamp":1769996194,"startTime":"0","endTime":"0","summary":"证券之星2月2日盘中消息,9点33分双鹭药业(002038)触及跌停板。其所属行业化学制药目前下跌。领涨股为北陆药业。该股为长寿药NMN,疫苗,创新药概念热股。1月30日的资金流向数据方面,主力资金净流入350.52万元,占总成交额1.68%,游资资金净流入843.09万元,占总成交额4.04%,散户资金净流出1193.61万元,占总成交额5.71%。近5日资金流向一览见下表:双鹭药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200004601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","002038"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588702547","title":"双鹭药业:奥司他韦订单数量有所增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702547","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588702547?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:51","pubTimestamp":1764636675,"startTime":"0","endTime":"0","summary":"证券之星消息,双鹭药业(002038)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司有生产用于治疗流感的奥斯他韦吗!现在产量如何?双鹭药业回复:您好,目前奥司他韦订单数量有所增加,其与其他抗流感类药物的具体销售情况公司也在密切关注。谢谢关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002038","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588702555","title":"双鹭药业:截至2025年9月30日股东总户数为54,779","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588702555?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:48","pubTimestamp":1764636493,"startTime":"0","endTime":"0","summary":"证券之星消息,双鹭药业(002038)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问:请问,截至2025年11月20日,公司的股东人数是多少?谢谢。双鹭药业回复:您好, 公司会在定期报告中披露股东人数变化,截至2025年9月30日,公司股东总户数为54,779。谢谢关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002038","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518507218","title":"双鹭药业收盘上涨1.02%,滚动市盈率86.04倍,总市值70.89亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518507218","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518507218?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:26","pubTimestamp":1741595198,"startTime":"0","endTime":"0","summary":"3月10日,双鹭药业今日收盘6.9元,上涨1.02%,滚动市盈率PE达到86.04倍,总市值70.89亿元。从行业市盈率排名来看,公司所处的生物制品行业市盈率平均41.57倍,行业中值37.39倍,双鹭药业排名第66位。股东方面,截至2024年9月30日,双鹭药业股东户数61868户,较上次减少1924户,户均持股市值35.28万元,户均持股数量2.76万股。北京双鹭药业股份有限公司主要专注于基因工程及相关药物的研究开发和生产经营,紧紧围绕疾病谱的变化布局研发和生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/10162648625643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002038","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779051348843,"stockEarnings":[{"period":"1week","weight":-0.06},{"period":"1month","weight":-0.2429},{"period":"3month","weight":-0.0393},{"period":"6month","weight":-0.2429},{"period":"1year","weight":-0.0703},{"period":"ytd","weight":-0.171}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京双鹭药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"68769人(较上一季度减少22.77%)","perCapita":"12388股","listingDate":"2004-09-09","address":"北京市海淀区阜石路69号碧桐园1号楼4层","registeredCapital":"102735万元","survey":" 北京双鹭药业股份有限公司的主营业务是基因工程及相关药物的研究开发和生产经营。公司的主要产品是生物、生化药、化学药。公司系国家火炬计划重点高新技术企业、国家技术创新示范企业、中关村生物产业创新基地、北京市中关村核心区生物工程和新医药产业联盟理事长单位、北京市工业企业知识产权运用示范企业、北京市国际科技合作基地、北京市高新技术成果转化示范企业,海淀园博士后科研工作站,北京市“G20”一期工程优秀企业、二期入选企业,中关村“十百千工程”重点培育企业,全资子公司双鹭生物被评为北京市“专精特新”中小企业。2025年公司核心竞争力未发生重大变化。","listedPrice":12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"双鹭药业(002038)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供双鹭药业(002038)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"双鹭药业,002038,双鹭药业股票,双鹭药业股票老虎,双鹭药业股票老虎国际,双鹭药业行情,双鹭药业股票行情,双鹭药业股价,双鹭药业股市,双鹭药业股票价格,双鹭药业股票交易,双鹭药业股票购买,双鹭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"双鹭药业(002038)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供双鹭药业(002038)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}